logo

For the Inventor, By the Inventor

Greenwood, IN, United States of America

Bernard J Abbott

This inventor holds 19 USPTO granted patents, primarily in Cyclic Peptides. Top assignee: Eli Lilly and Company. Active years: 1977-1985.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bernard J Abbott. Retrieved from https://idiyas.com/inventor/bernard-j-abbott

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19

% Patents Active = 100.0

Average Co-Inventor Count = 2.2

ph-index = 12

Forward Citations = 304(Granted Patents)


Company Filing History:

goldMedal19 out of 4,517 
 
Eli Lilly and Company
 patents

Years Active: 1977-1985

Loading Chart...
Areas of Expertise:
Cyclic Peptides
A-21978C
A-30912
Enzymatic Deesterification
Antibiotic Modifications
Mycophenolic Acid
Nucleus Derivatives
Microbiological Modification
19 patents (USPTO):Explore Patents
1. 4537717 - Derivatives of A-21978C cyclic peptides (1985-08-27),
2. 4524135 - A-21978C cyclic peptides (1985-06-18),
3. 4482487 - A-21978C cyclic peptides (1984-11-13),
4. 4322338 - Derivatives of A-30912B nucleus (1982-03-30),
5. 4320054 - Derivatives of A-30912H nucleus (1982-03-16),
6. 4320053 - Derivatives of A-30912D nucleus (1982-03-16),
7. 4320052 - Derivatives of A-30912A nucleus (1982-03-16),
8. 4316955 - Enzymatic deesterification of cephalosporin methyl esters (1982-02-23),
9. 4304716 - S 31794/F-1 Nucleus (1981-12-08),
10. 4299763 - A-30912B Nucleus (1981-11-10),
11. 4299762 - A-30912D Nucleus (1981-11-10),
12. 4293490 - A-30912H Nuclei (1981-10-06),
13. 4293482 - A-30912A Nucleus (1981-10-06),
14. 4287302 - Microbiological modification of antibiotic A23187 esters (1981-09-01),
15. 4287120 - Derivatives of S31794/F-1 nucleus (1981-09-01),

Title: **Bernard J Abbott: Innovator in Cyclic Peptide Derivatives**

Introduction

Bernard J Abbott is a renowned inventor based in Greenwood, IN, with a notable contribution to the pharmaceutical field. He holds an impressive total of 19 patents, predominantly focused on A-21978C cyclic peptides and their derivatives, marking him as a significant figure in medicinal chemistry and antibiotic development.

Latest Patents

Among his latest innovations, Abbott's patents include derivatives of A-21978C cyclic peptides. These patents detail a range of compounds represented by specific chemical formulas that demonstrate unique structural characteristics. For instance, the A-21978C cyclic peptides are designed with variations in groups that influence their chemical properties and potential applications. His work emphasizes the systematic approach to synthesizing these compounds, which have shown promise as intermediates in developing new semi-synthetic antibacterial agents.

Career Highlights

Currently, Abbott is affiliated with Eli Lilly and Company, a leader in the global pharmaceutical industry. His role involves extensive research and development related to antibiotic agents, aimed at enhancing existing treatments and discovering new therapeutic pathways. Through his work, Abbott has played a critical role in advancing the understanding and utilization of cyclic peptides in medicine.

Collaborations

In his professional journey, Abbott collaborates with esteemed colleagues such as David S Fukuda and Manuel Debono. These partnerships have facilitated a cooperative environment that fosters innovation and rigorous scientific exploration, contributing significantly to the success of their joint endeavors in pharmaceutical research.

Conclusion

Bernard J Abbott stands as a pivotal inventor in the realm of cyclic peptides, with a strong portfolio that showcases his dedication to improving healthcare through innovative scientific solutions. His ongoing contributions at Eli Lilly and Company highlight his commitment to combating bacterial infections and advancing medical therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…